A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
Low urgency

Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness

Detected July 16, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

FDA determined that TOVALT ODT (zolpidem tartrate) orally disintegrating tablets, 5 mg and 10 mg, were not withdrawn from sale for safety or effectiveness reasons. This allows ANDA holders to continue referencing the drug as a Reference Listed Drug (RLD) and supports generic competition.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Generic/ANDA manufacturers and branded drug makers involved with zolpidem tartrate ODT products should confirm how it applies to their specific situation before acting. There is a time constraint attached: None. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

FDA confirmed that TOVALT ODT was not withdrawn for safety/effectiveness, preserving its status as an RLD for ANDA referencing.

Who it affects

Generic/ANDA manufacturers and branded drug makers involved with zolpidem tartrate ODT products

What you must do

No immediate action required; monitor for any future changes to RLD status.

Deadline

None

Source: https://www.federalregister.gov/documents/2026/07/09/2026-13820/determination-that-tovalt-odt-zolpidem-tartrate-orally-disintegrating-tablets-5-milligrams-and-10

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)